Korean J Hematol.
1998 Aug;33(2):295-299.
Sweet Syndrome Developed in a Patient of Acute Promyelocytic Leukemia During Remission Induction Therapy with All-trans Retinoic Acid
- Affiliations
-
- 1Division of Hematology-Oncology, Taejon St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.
- 2Department of Internal Medicine, Taejon St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.
Abstract
- All-trans retinoic acid (RA) is recognized to be a drug of choice in remission induction of acute promyelocytic leukemia (APL), with some side effects including retinoic acid syndrome. But Sweet syndrome in association with RA is usually not serious nor well recognized. Early recognition of Sweet syndrome is important because additional therapy for this syndrome except steroid is not necessary. We report a case of Sweet syndrome developed in a patient of APL during remission induction therapy with RA.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- All-trans Retinoic Acid induced Myositis in a Patient with Acute Promyelocytic Leukemia
- Sweet's syndrome during the treatment of acute promyelocytic leukemia with all-trans retinoic acid
- All-trans Retinoic Acid-induced Nephrotic-range Proteinuria in a Patient with Acute Promyelocytic Leukemia
- Reversible Symptomatic Myocarditis Induced by All-Trans Retinoic Acid Administration during Induction Treatment of Acute Promyelocytic Leukemia: Rare Cardiac Manifestation as a Retinoic Acid Syndrome
- Remission induction using arsenic trioxide in acute promyelocytic leukemia
